Orphan designation: Treatment of sickle cell disease, 05/08/2013 Withdrawn
Submitted by Anonymous (not verified) on 13 May 2026 - 13:39
Orphan designation: Treatment of sickle cell disease, 05/08/2013 Withdrawn
Timetable: Extension application - ATMP
Submitted by Anonymous (not verified) on 13 May 2026 - 13:30
Timetable: Extension application - ATMP
HMPC meetings in 2025 and 2026
Submitted by Anonymous (not verified) on 13 May 2026 - 11:30
HMPC meetings in 2025 and 2026
HMPC: overview of assessment work - priority list
Submitted by Anonymous (not verified) on 13 May 2026 - 11:00
HMPC: overview of assessment work - priority list
Development and manufacture of synthetic peptides - Scientific guideline
Submitted by Anonymous (not verified) on 12 May 2026 - 15:49
Development and manufacture of synthetic peptides - Scientific guideline
Parallel scientific advice and special development aspects or product types
Submitted by Anonymous (not verified) on 12 May 2026 - 15:34
Parallel scientific advice and special development aspects or product types
Other fees and charges for medicinal products for human use, veterinary medicinal products and consultations on medical devices
Submitted by Anonymous (not verified) on 12 May 2026 - 15:15
Other fees and charges for medicinal products for human use, veterinary medicinal products and consultations on medical devices
Human medicines European public assessment report (EPAR): Xbonzy, denosumab, Date of authorisation: 17/11/2025, Revision: 2, Status: Authorised
Submitted by Anonymous (not verified) on 12 May 2026 - 15:08
Human medicines European public assessment report (EPAR): Xbonzy, denosumab, Date of authorisation: 17/11/2025, Revision: 2, Status: Authorised
Human medicines European public assessment report (EPAR): Evrenzo, roxadustat, Date of authorisation: 18/08/2021, Revision: 9, Status: Authorised
Submitted by Anonymous (not verified) on 12 May 2026 - 15:00
Human medicines European public assessment report (EPAR): Evrenzo, roxadustat, Date of authorisation: 18/08/2021, Revision: 9, Status: Authorised
Human medicines European public assessment report (EPAR): Olazax Disperzi, olanzapine, Date of authorisation: 10/12/2009, Revision: 13, Status: Authorised
Submitted by Anonymous (not verified) on 12 May 2026 - 14:45
Human medicines European public assessment report (EPAR): Olazax Disperzi, olanzapine, Date of authorisation: 10/12/2009, Revision: 13, Status: Authorised